GLP-1 Drugs: Beyond Diabetes and Weight

GLP-1 meds are exploding in popularity—over 25,000 per 100,000 diabetics, 12,800 per 100,000 for obesity, and 5,500 per 100,000 in the general population are now on them quarterly. Originally for diabetes, these drugs now tackle obesity, fatty liver, and even sleep apnea—with new triple-action versions in late-stage trials. Public awareness is driving demand, and research hints at benefits for PCOS and dementia risk reduction. While generally safe and side effects usually fade, they’re not magic bullets—they need diet and exercise to prevent muscle loss. Avoid unregulated compounded versions; these are long-term management tools, not quick fixes. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/11c6dfc1fca5f1f3